STIM vs. DRTS, ELMD, INGN, NYXH, ZYXI, CATX, LUNG, RCEL, AVR, and OBIO
Should you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include Alpha Tau Medical (DRTS), Electromed (ELMD), Inogen (INGN), Nyxoah (NYXH), Zynex (ZYXI), Perspective Therapeutics (CATX), Pulmonx (LUNG), AVITA Medical (RCEL), Anteris Technologies Global (AVR), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry.
Neuronetics vs.
Alpha Tau Medical (NASDAQ:DRTS) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
In the previous week, Neuronetics had 2 more articles in the media than Alpha Tau Medical. MarketBeat recorded 5 mentions for Neuronetics and 3 mentions for Alpha Tau Medical. Alpha Tau Medical's average media sentiment score of 0.33 beat Neuronetics' score of 0.24 indicating that Alpha Tau Medical is being referred to more favorably in the media.
2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by company insiders. Comparatively, 9.8% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Alpha Tau Medical presently has a consensus price target of $8.00, indicating a potential upside of 140.96%. Neuronetics has a consensus price target of $4.67, indicating a potential upside of 35.27%. Given Alpha Tau Medical's stronger consensus rating and higher probable upside, research analysts plainly believe Alpha Tau Medical is more favorable than Neuronetics.
Alpha Tau Medical has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Neuronetics has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500.
Alpha Tau Medical has higher earnings, but lower revenue than Neuronetics. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.
Alpha Tau Medical has a net margin of 0.00% compared to Neuronetics' net margin of -50.09%. Alpha Tau Medical's return on equity of -38.62% beat Neuronetics' return on equity.
Neuronetics received 109 more outperform votes than Alpha Tau Medical when rated by MarketBeat users. However, 70.37% of users gave Alpha Tau Medical an outperform vote while only 68.45% of users gave Neuronetics an outperform vote.
Summary
Alpha Tau Medical beats Neuronetics on 10 of the 17 factors compared between the two stocks.
Get Neuronetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuronetics Competitors List
Related Companies and Tools
This page (NASDAQ:STIM) was last updated on 2/4/2025 by MarketBeat.com Staff
